Flipper,
I think that they will enter into some forms of partnerships over the next year. It has always been my opinion and hope that they will partner up with one or more BP’s in regard to a number of various cancer indications. I don’t think the first step will be a buy out, though it could come at a later time through the partnerships. I think LP will be willing to enter into partnerships with little to no equity in NWBO, but with exclusive rights in Mucidencel for certain types of cancer. This is a way for NWBO to maximize the value of Murcidencel and still be able to maximize the later price for the company. This also gives BP a way to acquire what they need, without having a mutiny among their shareholders for over paying for NWBO at this time. I would have expected this to happen prior to many of the future milestones with bonuses for each milestone achieve, but it could also happen after they achieve more milestones.
They cannot sit idle by, which is why they continue to move on with the company as they see prudent. The points you mention will also be important should they enter into partnerships, as they are necessary for the future. JMHO
Market Data 
Markets 
AI
